Cognition TherapeuticsCGTX Market cap $17.5M
About: Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Employees: 25
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
75% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 8
2% less funds holding
Funds holding: 47 [Q1] → 46 (-1) [Q2]
4.93% less ownership
Funds ownership: 18.19% [Q1] → 13.26% (-4.93%) [Q2]
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
32% less capital invested
Capital invested by funds: $12.9M [Q1] → $8.82M (-$4.09M) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Raghuram Selvaraju 39% 1-year accuracy 113 / 288 met price target | 1,049%upside $5 | Buy Maintained | 12 Aug 2024 |
B. Riley Securities Mayank Mamtani 59% 1-year accuracy 16 / 27 met price target | 130%upside $1 | Neutral Downgraded | 6 Aug 2024 |
HC Wainwright & Co. Raghuram Selvaraju 39% 1-year accuracy 113 / 288 met price target | 1,509%upside $7 | Buy Maintained | 1 Aug 2024 |